Adrienne Asch: A Career at the Intersection of Bioethics and Disability Studies
By Sara Bergstresser,
Voices in Bioethics
| 03. 12. 2014
The first time I heard Adrienne Asch speak, she had assumed her role as a respected and influential member of the Disability Studies field. Later, as a student of Bioethics, I discovered that she was also a respected and influential Bioethicist. Who was this scholar with such expertise in two fields, and why did her contribution to each field have to be discovered separately? Asch passed away in November of 2013. Widely missed and memorialized in these two fields, I realized that there must be a third form of recognition for her pioneering work at the intersection of Disability Studies and Bioethics.
Asch was born in New York in 1946. Born premature, she developed retinopathy from too much oxygen in her incubator, thus losing her vision (Roberts 2013). Asch’s own difficulty in finding employment after graduating from Swarthmore College with a Bachelor’s degree in Philosophy made her keenly aware of disability as a civil rights issue (Fox 2013). She went on to study Social Work and Social Psychology at Columbia University and in 2005, she was recruited to direct the...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...
By Antonio Regalado, MIT Technology Review | 10.31.2025
A West Coast biotech entrepreneur says he’s secured $30 million to form a public-benefit company to study how to safely create genetically edited babies, marking the largest known investment into the taboo technology.
The new company, called Preventive, is...